CHRS - Coherus BioSciences, Inc.

QQQ $ 482.88 $ 2.24 (0.47 %)

DIA $ 408.91 $ 0.43 (0.11 %)

SPY $ 560.81 $ 1.92 (0.34 %)

TLT $ 98.72 $ 0.06 (0.06 %)

GLD $ 232.16 $ -0.31 (-0.13 %)

Previous Close

$ 1.34

Open

Bid

$ 1.33 x 1,364

Ask

$ 1.34 x 5,500

Day's Range

-- - --

52 Week Range

$ 1.20 - $ 5.47

Volume

2,097,023

Average Volume

Market Cap

153.86M

Beta (5Y Monthly)

$ 1.28

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	03-15-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	03-06-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-23-2022	12-31-2021	10-K
12	11-08-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-05-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	03-08-2018	12-31-2017	10-K
28	11-06-2017	09-30-2017	10-Q
29	08-07-2017	06-30-2017	10-Q
30	05-08-2017	03-31-2017	10-Q
31	03-14-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-09-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-10-2015	09-30-2015	10-Q
37	08-10-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	03-23-2015	12-31-2014	10-K
40	12-15-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

UBS Downgrades Coherus BioSciences to Neut...
08/16/2024 11:31:33

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:CHRS) from Buy to Neutral and lowers the price target from ...

Coherus BioSciences Sees FY24 R&D And SG&A...
08/08/2024 21:10:43

Coherus BioSciences Q2 2024 Adj. EPS $(0.1...
08/08/2024 20:21:44

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $...

HC Wainwright & Co. Reiterates Buy on Cohe...
08/05/2024 10:51:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...

Baird Maintains Outperform on Coherus BioS...
07/01/2024 11:20:29

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $9...

Coherus BioSciences To Divest YUSIMRY In $...
06/27/2024 12:28:23

HC Wainwright & Co. Reiterates Buy on Cohe...
05/24/2024 10:26:23

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...

Truist Securities Maintains Buy on Coherus...
05/13/2024 12:19:13

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

HC Wainwright & Co. Maintains Buy on Coher...
05/10/2024 19:37:15

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price tar...

Coherus BioSciences Q1 2024 Adj EPS $(0.32...
05/09/2024 21:15:21

Coherus Announces Full Repayment of Pharma...
05/09/2024 12:46:17

New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of L...

Coherus To Collaborate With Cancer Researc...
05/08/2024 13:01:49

Coherus Presents Preclinical Data For CHS-...
04/08/2024 12:34:02

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, le...

HC Wainwright & Co. Maintains Buy on Coher...
03/20/2024 11:19:10

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price tar...

HC Wainwright & Co. Reiterates Buy on Cohe...
03/14/2024 11:33:18

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price...

Coherus BioSciences Sees FY24 R&D And SG&A...
03/13/2024 20:25:39

Recap: Coherus BioSciences Q4 Earnings
03/13/2024 20:05:06

Coherus BioSciences Q4 2023 Adj EPS $(0.62...
03/13/2024 20:03:43

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of...

Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

Earnings Preview For Coherus BioSciences
03/12/2024 16:00:41